Healthcare Equipment and Supplies
Company Overview of Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology for treating eye diseases and conditions. The company offers ReSure Sealant, a synthetic ocular sealant in sealing clear corneal incisions following cataract surgery. Its products also include Dexamethasone Punctum Plug, a drug-eluting punctum plug; Travoprost Punctum Plug or the treatment of glaucoma and ocular hypertension; Moxifloxacin Punctum Plug for the treatment of bacterial conjunctivitis; and posterior segment injections. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered ...
36 Crosby Drive
Bedford, MA 01730
Founded in 2006
Key Executives for Ocular Therapeutix, Inc.
Total Annual Compensation: $254.9K
Chief Operating Officer
Total Annual Compensation: $362.5K
Executive Vice President of Clinical
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2013.
Ocular Therapeutix, Inc. Key Developments
Ocular Therapeutix, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:45 AM
Sep 3 14
Ocular Therapeutix, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:45 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Amarpreet Sawhney, Founder, Chairman, Chief Executive Officer and President.
Ocular Therapeutix, Inc. Reports Unaudited Earnings Results for the Three Months and Six Months Ended June 30, 2014; Provides Anticipated Clinical Milestones and Development Plans for the Fourth Quarter of 2014
Aug 28 14
Ocular Therapeutix, Inc. reported unaudited earnings results for the three months and six months ended June 30, 2014. For the three months, the company's revenue was $97,000. Loss from operations was $5,946,000 compared to $2,989,000 a year ago. Net loss attributable to common stockholders was $6,397,000 or $2.10 per basic and diluted share compared to $3,099,000 $1.19 per basic and diluted share a year ago. The company reported a sharply wider net loss for Second Quarter ended June 30 due to increased non-cash charges and operating expenses during the period.
For the six months, the company's revenue was $124,000. Loss from operations was $12,771,000 compared to $6,049,000 a year ago. Net loss attributable to common stockholders was $13,411,000 or $4.54 per basic and diluted share compared to $6,307,000 $2.45 per basic and diluted share a year ago.
The company provided anticipated clinical milestones and development plans for the fourth quarter of 2014. During the fourth quarter of 2014, the company intends to initiate a Phase 2b clinical trial of OTX-TP for the treatment of glaucoma and ocular hypertension. During the fourth quarter of 2014, Ocular expects to release Phase 2 clinical trial data of OTX-DP for the treatment of chronic allergic conjunctivitis. A total of 60 patients have been randomized 1:1 to receive either OTX-DP or a proprietary placebo punctum plug, using a Modified Conjunctival Allergen Challenge Model (CAC(TM)). OTX-DP is administered as a one-time sustained release corticosteroid with a four-week release. Primary endpoints of the Phase 2 trial include ocular itching and conjunctival redness.
Ocular Therapeutix, Inc. Announces Resignation of Alan Crane from Board of Directors, Effective July 30, 2014
Jul 30 14
As anticipated and as disclosed in the prospectus related to the initial public offering of shares of common stock by Ocular Therapeutix, Inc., Mr. Alan Crane resigned from the company's board of directors effective as of July 30, 2014 immediately prior to the closing of the IPO. Mr. Crane's resignation was not related to any disagreements with the company on any matters relating to the company's operations, policies or practices. As also disclosed in the prospectus related to the IPO, Mr. Crane's resignation was preceded by the appointment and election of Mr. Bruce Peacock to the company's board of directors in July 2014 prior to the IPO.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|